{
  "adapter_spec": {
    "method": "multiple_choice_joint",
    "global_prefix": "",
    "global_suffix": "",
    "instructions": "Answer A for yes, B for no or C for maybe. Do not include any explanation or additional text. Output only the letter on a single line.\n",
    "input_prefix": "Question: ",
    "input_suffix": "\n",
    "reference_prefix": "A. ",
    "reference_suffix": "\n",
    "chain_of_thought_prefix": "",
    "chain_of_thought_suffix": "\n",
    "output_prefix": "Answer: ",
    "output_suffix": "\n",
    "instance_prefix": "\n",
    "substitutions": [],
    "max_train_instances": 0,
    "max_eval_instances": 5,
    "num_outputs": 5,
    "num_train_trials": 1,
    "num_trials": 1,
    "sample_train": true,
    "model_deployment": "my_org/deepseek-r1",
    "model": "my_org/deepseek-r1",
    "temperature": 0.0,
    "max_tokens": 1,
    "stop_sequences": [
      "\n"
    ],
    "multi_label": false
  },
  "request_states": [
    {
      "instance": {
        "input": {
          "text": "Context: Background. An unknown number of colorectal cancers could be due to missed adenomas during previous endoscopy. Data in the literature are sparse. A large cross-sectional study was done in a prospective database of all patients diagnosed with colorectal cancer.\nMethods. All consecutive endoscopies over a period of 15 years, in which colorectal cancer was diagnosed were included. All patients who underwent more than one endoscopy and in whom ultimately cancer was diagnosed were studied separately.\nResults. Colorectal cancer was diagnosed in 835 patients. Twenty-five patients underwent a previous endoscopy without a cancer diagnosis. These 25 patients were divided into three groups according to the time between the endoscopy in which the cancer was detected and the previous endoscopy. Five out of these 25 patients underwent regular surveillance. Only 11 patients had no argument for regular follow-up. Assuming that these cancers developed from an adenoma than only 11 out of 835 (1.3%) cancers were missed in the adenoma phase. There was no difference in the size of the tumour between the three groups of patients.\n\nQuestion: Are many colorectal cancers due to missed adenomas?\n"
        },
        "references": [
          {
            "output": {
              "text": "yes"
            },
            "tags": []
          },
          {
            "output": {
              "text": "no"
            },
            "tags": [
              "correct"
            ]
          },
          {
            "output": {
              "text": "maybe"
            },
            "tags": []
          }
        ],
        "split": "test",
        "id": "id993"
      },
      "train_trial_index": 0,
      "output_mapping": {
        "A": "yes",
        "B": "no",
        "C": "maybe"
      },
      "request": {
        "model_deployment": "my_org/deepseek-r1",
        "model": "my_org/deepseek-r1",
        "embedding": false,
        "prompt": "Answer A for yes, B for no or C for maybe. Do not include any explanation or additional text. Output only the letter on a single line.\n\nQuestion: Context: Background. An unknown number of colorectal cancers could be due to missed adenomas during previous endoscopy. Data in the literature are sparse. A large cross-sectional study was done in a prospective database of all patients diagnosed with colorectal cancer.\nMethods. All consecutive endoscopies over a period of 15 years, in which colorectal cancer was diagnosed were included. All patients who underwent more than one endoscopy and in whom ultimately cancer was diagnosed were studied separately.\nResults. Colorectal cancer was diagnosed in 835 patients. Twenty-five patients underwent a previous endoscopy without a cancer diagnosis. These 25 patients were divided into three groups according to the time between the endoscopy in which the cancer was detected and the previous endoscopy. Five out of these 25 patients underwent regular surveillance. Only 11 patients had no argument for regular follow-up. Assuming that these cancers developed from an adenoma than only 11 out of 835 (1.3%) cancers were missed in the adenoma phase. There was no difference in the size of the tumour between the three groups of patients.\n\nQuestion: Are many colorectal cancers due to missed adenomas?\n\nA. yes\nB. no\nC. maybe\nAnswer:",
        "temperature": 0.0,
        "num_completions": 1,
        "top_k_per_token": 5,
        "max_tokens": 1,
        "stop_sequences": [],
        "echo_prompt": false,
        "top_p": 1,
        "presence_penalty": 0,
        "frequency_penalty": 0
      },
      "result": {
        "success": true,
        "embedding": [],
        "completions": [
          {
            "text": "B",
            "logprob": 0,
            "tokens": [
              {
                "text": "B",
                "logprob": 0
              }
            ],
            "finish_reason": {
              "reason": "length"
            },
            "thinking": {
              "text": "Okay, let me think about this. The question is asking whether many colorectal cancers are due to missed adenomas during previous endoscopies. \n\nLooking at the context provided: The study included 835 patients diagnosed with colorectal cancer. Out of these, 25 had a previous endoscopy where cancer wasn't found. Then they divided those 25 into groups based on time between endoscopies.\n\nThe key point here is that only 5 were under regular surveillance, and 11 didn't have a reason for regular follow-up. The conclusion mentioned that if assuming cancers developed from adenomas, then 11 out of 835 (1.3%) were missed in the adenoma phase. So the researchers are suggesting that only a small percentage (1.3%) of the cancers might be due to missed adenomas. \n\nThe answer options are A for yes, B for no, or C for maybe. Since the conclusion states that only 1.3% were potentially missed, that's a low percentage. The authors imply that not many cancers are due to this factor. So the answer should be B. No.\n"
            }
          }
        ],
        "cached": false,
        "request_time": 6.777251720428467,
        "request_datetime": 1769868026
      },
      "num_train_instances": 0,
      "prompt_truncated": false,
      "num_conditioning_tokens": 0
    },
    {
      "instance": {
        "input": {
          "text": "Context: Objective. To investigate the relevance of the Symptom Checklist 90-R Obsessive-Compulsive subscale to cognition in individuals with brain tumor.\nDesign. A prospective study of patients assessed with a neuropsychological test battery.\nSetting. A university medical center.\nPatients. Nineteen adults with biopsy-confirmed diagnoses of malignant brain tumors were assessed prior to aggressive chemotherapy.\nMain Outcome Measures. Included in the assessment were the Mattis Dementia Rating Scale, California Verbal Learning Test, Trail Making Test B, Symptom Checklist 90-R, Mood Assessment Scale, Beck Anxiety Inventory, and Chronic Illness Problem Inventory.\nResults. The SCL 90-R Obsessive-Compulsive subscale was not related to objective measures of attention, verbal memory, or age. It was related significantly to symptoms of depression (r = .81, P<.005), anxiety (r = .66, P<.005), and subjective complaints of memory problems (r = .75, P<.005). Multivariate analyses indicated that reported symptoms of depression contributed 66% of the variance in predicting SCL 90-R Obsessive-Compulsive Scores, whereas symptoms of anxiety contributed an additional 6% (P<.0001).\n\nQuestion: Does the SCL 90-R obsessive-compulsive dimension identify cognitive impairments?\n"
        },
        "references": [
          {
            "output": {
              "text": "yes"
            },
            "tags": [
              "correct"
            ]
          },
          {
            "output": {
              "text": "no"
            },
            "tags": []
          },
          {
            "output": {
              "text": "maybe"
            },
            "tags": []
          }
        ],
        "split": "test",
        "id": "id859"
      },
      "train_trial_index": 0,
      "output_mapping": {
        "A": "yes",
        "B": "no",
        "C": "maybe"
      },
      "request": {
        "model_deployment": "my_org/deepseek-r1",
        "model": "my_org/deepseek-r1",
        "embedding": false,
        "prompt": "Answer A for yes, B for no or C for maybe. Do not include any explanation or additional text. Output only the letter on a single line.\n\nQuestion: Context: Objective. To investigate the relevance of the Symptom Checklist 90-R Obsessive-Compulsive subscale to cognition in individuals with brain tumor.\nDesign. A prospective study of patients assessed with a neuropsychological test battery.\nSetting. A university medical center.\nPatients. Nineteen adults with biopsy-confirmed diagnoses of malignant brain tumors were assessed prior to aggressive chemotherapy.\nMain Outcome Measures. Included in the assessment were the Mattis Dementia Rating Scale, California Verbal Learning Test, Trail Making Test B, Symptom Checklist 90-R, Mood Assessment Scale, Beck Anxiety Inventory, and Chronic Illness Problem Inventory.\nResults. The SCL 90-R Obsessive-Compulsive subscale was not related to objective measures of attention, verbal memory, or age. It was related significantly to symptoms of depression (r = .81, P<.005), anxiety (r = .66, P<.005), and subjective complaints of memory problems (r = .75, P<.005). Multivariate analyses indicated that reported symptoms of depression contributed 66% of the variance in predicting SCL 90-R Obsessive-Compulsive Scores, whereas symptoms of anxiety contributed an additional 6% (P<.0001).\n\nQuestion: Does the SCL 90-R obsessive-compulsive dimension identify cognitive impairments?\n\nA. yes\nB. no\nC. maybe\nAnswer:",
        "temperature": 0.0,
        "num_completions": 1,
        "top_k_per_token": 5,
        "max_tokens": 1,
        "stop_sequences": [],
        "echo_prompt": false,
        "top_p": 1,
        "presence_penalty": 0,
        "frequency_penalty": 0
      },
      "result": {
        "success": true,
        "embedding": [],
        "completions": [
          {
            "text": "B",
            "logprob": 0,
            "tokens": [
              {
                "text": "B",
                "logprob": 0
              }
            ],
            "finish_reason": {
              "reason": "length"
            },
            "thinking": {
              "text": "Okay, let's tackle this question. The user is asking whether the SCL 90-R obsessive-compulsive subscale identifies cognitive impairments based on the study described.\n\nFirst, looking at the context. The study's objective is to check the relevance of the SCL 90-R's OC subscale to cognition in brain tumor patients. They did a prospective study with neuropsychological tests. The main outcome measures include various cognitive tests like the Mattis Dementia Rating Scale, California Verbal Learning Test, Trail Making Test B, etc. \n\nNow, the results section says the SCL 90-R OC subscale wasn't related to objective measures of attention, verbal memory, or age. Instead, it correlated with depression, anxiety, and subjective memory complaints. The multivariate analysis showed depression accounted for 66% variance, anxiety added 6%. \n\nSo the question is, does this OC subscale identify cognitive impairments? The key here is that the objective measures (like the actual neuropsych tests) weren't linked to the OC scores. The OC scale was linked to subjective complaints and mood issues. Cognitive impairments would be indicated by those objective tests. Since the OC scale didn't correlate with those, the answer should be no. The OC scale here is more tied to emotional symptoms rather than actual cognitive deficits. Therefore, the answer is B (no).\n"
            }
          }
        ],
        "cached": false,
        "request_time": 8.065946578979492,
        "request_datetime": 1769868026
      },
      "num_train_instances": 0,
      "prompt_truncated": false,
      "num_conditioning_tokens": 0
    },
    {
      "instance": {
        "input": {
          "text": "Context: Background. Implementation of the complex treatment strategies that have been shown to improve survival of patients with congestive heart failure (CHF) may require certain expertise. We wanted to examine the association between pattern of outpatient care and survival of patients with CHF.\nMethods. In a retrospective cohort study conducted with national Veterans Health Administration (VHA) databases, we examined the association between the pattern of outpatient care and survival in 11,661 patients discharged from VA hospitals between October 1, 1991, and September 30, 1992, with the primary diagnosis of CHF (cohort 1). Patients were divided into 4 groups, on the basis of their pattern of outpatient care over a 12-month period after discharge: 1) general medicine clinic visits only (GM-only); 2) cardiology clinic visits only (CARD-only); 3) general medicine and cardiology (MIXED) clinic visits; and 4) neither general medicine nor cardiology clinic visits (no-GM/CARD). We used the Cox proportional hazards model to evaluate 1-year survival, controlling for clinical and demographic factors. Consistency of our results was examined by performing identical analysis on a cohort of patients discharged from VHA hospitals between October 1, 1994, and September 30, 1995 (cohort 2, n = 10,141).\nResults. The overall 1-year mortality rate was 23% in the primary cohort. The unadjusted mortality rate was highest for patients in the no-GM/CARD follow up (29%) and lowest for patients in the MIXED group (19%). By use of the MIXED group as reference and adjusting for important clinical and demographic factors, the risk of death (risk ratio [95% CI]) was 1.12 (0.94-1.34) in the CARD-only group, 1.26 (1.15-1.38) in the GM-only group, and 1.48 (1.28-1.72) in the no-GM/CARD group. Cohort-2 results were consistent with cohort 1 for most covariates, and significant survival differences were again found between GM-only and the MIXED group (1.25 [1.14-1.37]).\n\nQuestion: Is specialty care associated with improved survival of patients with congestive heart failure?\n"
        },
        "references": [
          {
            "output": {
              "text": "yes"
            },
            "tags": [
              "correct"
            ]
          },
          {
            "output": {
              "text": "no"
            },
            "tags": []
          },
          {
            "output": {
              "text": "maybe"
            },
            "tags": []
          }
        ],
        "split": "test",
        "id": "id298"
      },
      "train_trial_index": 0,
      "output_mapping": {
        "A": "yes",
        "B": "no",
        "C": "maybe"
      },
      "request": {
        "model_deployment": "my_org/deepseek-r1",
        "model": "my_org/deepseek-r1",
        "embedding": false,
        "prompt": "Answer A for yes, B for no or C for maybe. Do not include any explanation or additional text. Output only the letter on a single line.\n\nQuestion: Context: Background. Implementation of the complex treatment strategies that have been shown to improve survival of patients with congestive heart failure (CHF) may require certain expertise. We wanted to examine the association between pattern of outpatient care and survival of patients with CHF.\nMethods. In a retrospective cohort study conducted with national Veterans Health Administration (VHA) databases, we examined the association between the pattern of outpatient care and survival in 11,661 patients discharged from VA hospitals between October 1, 1991, and September 30, 1992, with the primary diagnosis of CHF (cohort 1). Patients were divided into 4 groups, on the basis of their pattern of outpatient care over a 12-month period after discharge: 1) general medicine clinic visits only (GM-only); 2) cardiology clinic visits only (CARD-only); 3) general medicine and cardiology (MIXED) clinic visits; and 4) neither general medicine nor cardiology clinic visits (no-GM/CARD). We used the Cox proportional hazards model to evaluate 1-year survival, controlling for clinical and demographic factors. Consistency of our results was examined by performing identical analysis on a cohort of patients discharged from VHA hospitals between October 1, 1994, and September 30, 1995 (cohort 2, n = 10,141).\nResults. The overall 1-year mortality rate was 23% in the primary cohort. The unadjusted mortality rate was highest for patients in the no-GM/CARD follow up (29%) and lowest for patients in the MIXED group (19%). By use of the MIXED group as reference and adjusting for important clinical and demographic factors, the risk of death (risk ratio [95% CI]) was 1.12 (0.94-1.34) in the CARD-only group, 1.26 (1.15-1.38) in the GM-only group, and 1.48 (1.28-1.72) in the no-GM/CARD group. Cohort-2 results were consistent with cohort 1 for most covariates, and significant survival differences were again found between GM-only and the MIXED group (1.25 [1.14-1.37]).\n\nQuestion: Is specialty care associated with improved survival of patients with congestive heart failure?\n\nA. yes\nB. no\nC. maybe\nAnswer:",
        "temperature": 0.0,
        "num_completions": 1,
        "top_k_per_token": 5,
        "max_tokens": 1,
        "stop_sequences": [],
        "echo_prompt": false,
        "top_p": 1,
        "presence_penalty": 0,
        "frequency_penalty": 0
      },
      "result": {
        "success": true,
        "embedding": [],
        "completions": [
          {
            "text": "A",
            "logprob": 0,
            "tokens": [
              {
                "text": "A",
                "logprob": 0
              }
            ],
            "finish_reason": {
              "reason": "length"
            },
            "thinking": {
              "text": "Okay, let's see. The question is asking whether specialty care is associated with improved survival for CHF patients. The context provided is a study from the Veterans Health Administration comparing different outpatient care patterns.\n\nLooking at the methods, they divided patients into four groups based on who they saw after discharge: general medicine only, cardiology only, both, or neither. Then they looked at 1-year mortality using Cox models adjusting for variables.\n\nThe results show that the MIXED group (both general and cardiology) had the lowest unadjusted mortality at 19%. The adjusted risk ratios compare each group to the MIXED group. The CARD-only group had a risk ratio of 1.12, which isn't significant because the CI includes 1 (0.94-1.34). The GM-only and no-care groups had higher, significant risks. \n\nSo, the MIXED group was the reference. If specialty care (cardiology) alone was beneficial, then the CARD-only group should have lower risk. But their risk was higher, though not significantly. The MIXED group, which includes cardiology visits along with general medicine, had the best survival. That suggests that combining both might be better than either alone. However, since the CARD-only group wasn't significantly worse than MIXED, maybe having some cardiology input in the mixed group contributes to the better outcome. \n\nThe question is about specialty care (which would be cardiology here). The study seems to indicate that seeing both specialists and generalists (MIXED) is associated with the best survival. If the answer is \"yes\" (A), then specialty care is beneficial. But since the CARD-only group didn't show a significant benefit over MIXED (they were the reference), maybe the benefit is specifically when combined with general care. However, the conclusion could be that having some specialty involvement (as in MIXED) improves survival compared to general only or none. So the answer might be yes because mixed includes specialty care, which is better than not having it. The problem is, the CARD-only group didn't have a significant survival advantage. But compared to MIXED, GM-only had worse outcomes. So perhaps the presence of cardiology in the MIXED group contributes to better outcomes. Therefore, yes, specialty care association is there.\n"
            }
          }
        ],
        "cached": false,
        "request_time": 14.098922729492188,
        "request_datetime": 1769868026
      },
      "num_train_instances": 0,
      "prompt_truncated": false,
      "num_conditioning_tokens": 0
    },
    {
      "instance": {
        "input": {
          "text": "Context: Background. Treatment of elderly cancer patients has gained importance. One question regarding the treatment of metastatic spinal cord compression (MSCC) is whether elderly patients benefit from surgery in addition to radiotherapy? In attempting to answer this question, we performed a matched-pair analysis comparing surgery followed by radiotherapy to radiotherapy alone.\nPatients And Methods. Data from 42 elderly (age>\u200965 years) patients receiving surgery plus radiotherapy (S\u2009+\u2009RT) were matched to 84 patients (1:2) receiving radiotherapy alone (RT). Groups were matched for ten potential prognostic factors and compared regarding motor function, local control, and survival. Additional matched-pair analyses were performed for the subgroups of patients receiving direct decompressive surgery plus stabilization of involved vertebrae (DDSS, n\u2009=\u200981) and receiving laminectomy (LE, n\u2009=\u200945).\nResults. Improvement of motor function occurred in 21% after S\u2009+\u2009RT and 24% after RT (p\u2009=\u20090.39). The 1-year local control rates were 81% and 91% (p\u2009=\u20090.44), while the 1-year survival rates were 46% and 39% (p\u2009=\u20090.71). In the matched-pair analysis of patients receiving DDSS, improvement of motor function occurred in 22% after DDSS\u2009+\u2009RT and 24% after RT alone (p\u2009=\u20090.92). The 1-year local control rates were 95% and 89% (p\u2009=\u20090.62), and the 1-year survival rates were 54% and 43% (p\u2009=\u20090.30). In the matched-pair analysis of patients receiving LE, improvement of motor function occurred in 20% after LE\u2009+\u2009RT and 23% after RT alone (p\u2009=\u20090.06). The 1-year local control rates were 50% and 92% (p\u2009=\u20090.33). The 1-year survival rates were 32% and 32% (p\u2009=\u20090.55).\n\nQuestion: Do elderly patients benefit from surgery in addition to radiotherapy for treatment of metastatic spinal cord compression?\n"
        },
        "references": [
          {
            "output": {
              "text": "yes"
            },
            "tags": []
          },
          {
            "output": {
              "text": "no"
            },
            "tags": [
              "correct"
            ]
          },
          {
            "output": {
              "text": "maybe"
            },
            "tags": []
          }
        ],
        "split": "test",
        "id": "id553"
      },
      "train_trial_index": 0,
      "output_mapping": {
        "A": "yes",
        "B": "no",
        "C": "maybe"
      },
      "request": {
        "model_deployment": "my_org/deepseek-r1",
        "model": "my_org/deepseek-r1",
        "embedding": false,
        "prompt": "Answer A for yes, B for no or C for maybe. Do not include any explanation or additional text. Output only the letter on a single line.\n\nQuestion: Context: Background. Treatment of elderly cancer patients has gained importance. One question regarding the treatment of metastatic spinal cord compression (MSCC) is whether elderly patients benefit from surgery in addition to radiotherapy? In attempting to answer this question, we performed a matched-pair analysis comparing surgery followed by radiotherapy to radiotherapy alone.\nPatients And Methods. Data from 42 elderly (age>\u200965 years) patients receiving surgery plus radiotherapy (S\u2009+\u2009RT) were matched to 84 patients (1:2) receiving radiotherapy alone (RT). Groups were matched for ten potential prognostic factors and compared regarding motor function, local control, and survival. Additional matched-pair analyses were performed for the subgroups of patients receiving direct decompressive surgery plus stabilization of involved vertebrae (DDSS, n\u2009=\u200981) and receiving laminectomy (LE, n\u2009=\u200945).\nResults. Improvement of motor function occurred in 21% after S\u2009+\u2009RT and 24% after RT (p\u2009=\u20090.39). The 1-year local control rates were 81% and 91% (p\u2009=\u20090.44), while the 1-year survival rates were 46% and 39% (p\u2009=\u20090.71). In the matched-pair analysis of patients receiving DDSS, improvement of motor function occurred in 22% after DDSS\u2009+\u2009RT and 24% after RT alone (p\u2009=\u20090.92). The 1-year local control rates were 95% and 89% (p\u2009=\u20090.62), and the 1-year survival rates were 54% and 43% (p\u2009=\u20090.30). In the matched-pair analysis of patients receiving LE, improvement of motor function occurred in 20% after LE\u2009+\u2009RT and 23% after RT alone (p\u2009=\u20090.06). The 1-year local control rates were 50% and 92% (p\u2009=\u20090.33). The 1-year survival rates were 32% and 32% (p\u2009=\u20090.55).\n\nQuestion: Do elderly patients benefit from surgery in addition to radiotherapy for treatment of metastatic spinal cord compression?\n\nA. yes\nB. no\nC. maybe\nAnswer:",
        "temperature": 0.0,
        "num_completions": 1,
        "top_k_per_token": 5,
        "max_tokens": 1,
        "stop_sequences": [],
        "echo_prompt": false,
        "top_p": 1,
        "presence_penalty": 0,
        "frequency_penalty": 0
      },
      "result": {
        "success": true,
        "embedding": [],
        "completions": [
          {
            "text": "B",
            "logprob": 0,
            "tokens": [
              {
                "text": "B",
                "logprob": 0
              }
            ],
            "finish_reason": {
              "reason": "length"
            },
            "thinking": {
              "text": "Okay, so I need to figure out if elderly patients benefit from surgery plus radiotherapy compared to radiotherapy alone for metastatic spinal cord compression. Let me look at the study details.\n\nThe study did a matched-pair analysis. They had 42 patients in the surgery plus RT group and matched them 1:2 with 84 RT alone patients. The primary outcomes were motor function improvement, local control, and survival.\n\nLooking at the results for the main groups: motor function improvement was 21% vs 24%, which isn't a significant difference (p=0.39). Local control at 1 year was 81% vs 91%, p=0.44. Survival rates were 46% vs 39%, p=0.71. None of these are statistically significant, so no clear benefit from surgery here.\n\nThen they looked at subgroups. For DDSS (direct decompressive surgery plus stabilization), motor improvement was 22% vs 24% (p=0.92). Local control was 95% vs 89% (p=0.62), and survival 54% vs 43% (p=0.30). Again, no significant differences. For laminectomy (LE), motor improvement was 20% vs 23% (p=0.06), which is approaching significance but not quite. Local control here was 50% vs 92% (p=0.33), which seems like a big drop, but the p-value isn't significant. Survival same at 32% for both.\n\nSince none of the outcomes showed statistically significant differences between the surgery plus RT and RT alone groups in any of the analyses, the answer would be B (no). Even though some numbers look different, the p-values indicate that these differences could be due to chance. Therefore, the study doesn't support the conclusion that surgery provides a benefit here.\n"
            }
          }
        ],
        "cached": false,
        "request_time": 11.302502870559692,
        "request_datetime": 1769868026
      },
      "num_train_instances": 0,
      "prompt_truncated": false,
      "num_conditioning_tokens": 0
    },
    {
      "instance": {
        "input": {
          "text": "Context: Background. The criteria for administration of adjuvant radiation therapy after thymoma resection remains controversial, and it is unclear whether patients with Masaoka stage III thymoma benefit from adjuvant radiation. The goal of this report was to determine whether or not this group benefits from radiation therapy in disease-specific survival and disease-free survival.\nMethods. Case records of the Massachusetts General Hospital were retrospectively reviewed from 1972 to 2004. One hundred and seventy-nine patients underwent resection for thymoma, of which 45 had stage III disease.\nResults. Forty-five stage III patients underwent resection and in 36 it was complete. Thirty-eight stage III patients received radiation therapy. Baseline prognostic factors between radiated and nonradiated groups were similar. The addition of adjuvant radiotherapy did not alter local or distant recurrence rates in patients with stage III thymoma. Disease-specific survival at 10 years in stage III patients who did not receive radiation was 75% (95% confidence interval, 32% to 100%) and in patients who did receive radiation therapy it was 79% (95% confidence interval, 64% to 94%) (p = 0.21). The most common site of relapse was the pleura.\n\nQuestion: Adjuvant radiation of stage III thymoma: is it necessary?\n"
        },
        "references": [
          {
            "output": {
              "text": "yes"
            },
            "tags": []
          },
          {
            "output": {
              "text": "no"
            },
            "tags": [
              "correct"
            ]
          },
          {
            "output": {
              "text": "maybe"
            },
            "tags": []
          }
        ],
        "split": "test",
        "id": "id672"
      },
      "train_trial_index": 0,
      "output_mapping": {
        "A": "yes",
        "B": "no",
        "C": "maybe"
      },
      "request": {
        "model_deployment": "my_org/deepseek-r1",
        "model": "my_org/deepseek-r1",
        "embedding": false,
        "prompt": "Answer A for yes, B for no or C for maybe. Do not include any explanation or additional text. Output only the letter on a single line.\n\nQuestion: Context: Background. The criteria for administration of adjuvant radiation therapy after thymoma resection remains controversial, and it is unclear whether patients with Masaoka stage III thymoma benefit from adjuvant radiation. The goal of this report was to determine whether or not this group benefits from radiation therapy in disease-specific survival and disease-free survival.\nMethods. Case records of the Massachusetts General Hospital were retrospectively reviewed from 1972 to 2004. One hundred and seventy-nine patients underwent resection for thymoma, of which 45 had stage III disease.\nResults. Forty-five stage III patients underwent resection and in 36 it was complete. Thirty-eight stage III patients received radiation therapy. Baseline prognostic factors between radiated and nonradiated groups were similar. The addition of adjuvant radiotherapy did not alter local or distant recurrence rates in patients with stage III thymoma. Disease-specific survival at 10 years in stage III patients who did not receive radiation was 75% (95% confidence interval, 32% to 100%) and in patients who did receive radiation therapy it was 79% (95% confidence interval, 64% to 94%) (p = 0.21). The most common site of relapse was the pleura.\n\nQuestion: Adjuvant radiation of stage III thymoma: is it necessary?\n\nA. yes\nB. no\nC. maybe\nAnswer:",
        "temperature": 0.0,
        "num_completions": 1,
        "top_k_per_token": 5,
        "max_tokens": 1,
        "stop_sequences": [],
        "echo_prompt": false,
        "top_p": 1,
        "presence_penalty": 0,
        "frequency_penalty": 0
      },
      "result": {
        "success": true,
        "embedding": [],
        "completions": [
          {
            "text": "B",
            "logprob": 0,
            "tokens": [
              {
                "text": "B",
                "logprob": 0
              }
            ],
            "finish_reason": {
              "reason": "length"
            },
            "thinking": {
              "text": "Okay, let's see. The question is whether adjuvant radiation therapy is necessary for stage III thymoma after resection. The study looked at 45 stage III patients, with 36 having complete resection. Out of these, 38 received radiation. The key findings are that the radiation didn't change recurrence rates\u2014both local and distant. The disease-specific survival at 10 years was 75% without radiation and 79% with it, but the p-value was 0.21, which isn't statistically significant. So the conclusion is that adding radiation didn't really improve survival or recurrence. The most common relapse site was the pleura. Since there's no significant benefit shown here, maybe the answer is no, radiation isn't necessary. But wait, maybe the study isn't definitive because it's retrospective or small sample? The confidence intervals are wide for the non-radiated group (32-100%), which might indicate uncertainty. However, since the main results didn't show a significant difference, the answer might lean towards no.\n"
            }
          }
        ],
        "cached": false,
        "request_time": 6.694833517074585,
        "request_datetime": 1769868033
      },
      "num_train_instances": 0,
      "prompt_truncated": false,
      "num_conditioning_tokens": 0
    }
  ]
}